OraSure Technologies, Inc. (OSUR): Price and Financial Metrics


OraSure Technologies, Inc. (OSUR)

Today's Latest Price: $12.32 USD

0.32 (2.67%)

Updated Dec 1 6:55pm

Add OSUR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

OSUR Stock Summary

  • Price to trailing twelve month operating cash flow for OSUR is currently 760.54, higher than 99.57% of US stocks with positive operating cash flow.
  • The ratio of debt to operating expenses for Orasure Technologies Inc is higher than it is for about just 9.08% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for Orasure Technologies Inc; that's greater than it is for only 9.84% of US stocks.
  • Stocks that are quantitatively similar to OSUR, based on their financial statements, market capitalization, and price volatility, are STRM, TRUE, AEHR, CRTO, and SRI.
  • Visit OSUR's SEC page to see the company's official filings. To visit the company's web site, go to www.orasure.com.

OSUR Stock Price Chart Interactive Chart >

Price chart for OSUR

OSUR Price/Volume Stats

Current price $12.32 52-week high $19.75
Prev. close $12.00 52-week low $5.23
Day low $12.07 Volume 895,500
Day high $12.47 Avg. volume 1,559,086
50-day MA $13.43 Dividend yield N/A
200-day MA $12.43 Market Cap 883.75M

OraSure Technologies, Inc. (OSUR) Company Bio


OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company was founded in 1979 and is based in Bethlehem, Pennsylvania.


OSUR Latest News Stream


Event/Time News Detail
Loading, please wait...

OSUR Latest Social Stream


Loading social stream, please wait...

View Full OSUR Social Stream

Latest OSUR News From Around the Web

Below are the latest news stories about Orasure Technologies Inc that investors may wish to consider to help them evaluate OSUR as an investment opportunity.

Home/Self-Testing Market 2020-2027 Major Players Hitting the Reset Button || PRIMA Lab SA, bioLytical Laboratories Inc., OraSure Technologies, Inc., NecLife., Piramal Enterprises Ltd

DBMR has added a new report titled Home/Self-Testing Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken from consistent sources such

OpenPR | September 30, 2020

FDA OKs emergency use of new COVID-19 test with OraSure saliva collection devices

The FDA has approved emergency use authorization of a COVID-19 test kit developed at Quadrant Biosciences. The nod includes OraSure's (OSUR) ORAcollect-RNA device for the collection of saliva swab samples.OSUR says this is the sixth COVID-19 test using one of its collection devices approved for emergency use in the U.S., and the first...

Seeking Alpha | September 24, 2020

OraSure Technologies (OSUR) Investor Presentation - Slideshow

The following slide deck was published by OraSure Technologies, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 10, 2020

OraSure’s OMNIgene®·ORAL Device Included in EUA Granted to Clinical Reference Laboratory for Self-Collected SARS-CoV-2 Saliva Test

BETHLEHEM, Pa., July 31, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its OMNIgene®·ORAL (OM-505) saliva collection device is included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the United States, for SARS-CoV-2 testing. This is the fourth EUA to include a collection device manufactured and sold by the Company’s DNA Genotek subsidiary. The EUA authorizes CRL to use the OMNIgene®·ORAL device with CRL Rapid Response™, its saliva-based SARS-CoV-2 RT-PCR test that can be sel...

Yahoo | July 31, 2020

Clinical Reference Laboratory Receives FDA Emergency Use Authorization for Best-in-Class Self-Collected COVID-19 Saliva Test

Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it received FDA Emergency Use Authorization (EUA) and is scaling up capacity for CRL Rapid Response™, a saliva-based COVID-19 RT-PCR test that can be self-collected at home, work or any other setting. The test, shown in CRL's EUA studies to be more sensitive and accurate than the standard COVID-19 anterior nasal swab test, detects the presence of coronavirus in the saliva of the test taker. In addition, the test is more comfortable and easier to administer, is not "technique dependent" and virtually anyone can self-collect an adequate sample for testing, with test results available in 24-48 hours of receipt at CRL. CRL Rapid Response™ is r...

Yahoo | July 31, 2020

Read More 'OSUR' Stories Here

OSUR Price Returns

1-mo -17.23%
3-mo 14.82%
6-mo 19.21%
1-year 59.17%
3-year -27.66%
5-year 93.10%
YTD 53.42%
2019 -31.25%
2018 -38.07%
2017 114.81%
2016 36.34%
2015 -36.49%

Continue Researching OSUR

Here are a few links from around the web to help you further your research on Orasure Technologies Inc's stock as an investment opportunity:

Orasure Technologies Inc (OSUR) Stock Price | Nasdaq
Orasure Technologies Inc (OSUR) Stock Quote, History and News - Yahoo Finance
Orasure Technologies Inc (OSUR) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1382 seconds.